News

Axsome: Some Recent Setbacks, Some Recent Wins -- Still A Buy

Axsome is close to a $500m revenue per annum company with potential to achieve >$1bn per annum by 2030. Read the full AXSM stock analysis here.
Zacks Investment Research on MSN23h

HOLX vs. EXAS: Which Cancer Diagnostics Stock Should You Retain Now?

Amid the rising prevalence of cancer worldwide, significant strides have been made in the cancer diagnostics market to improve treatment outcomes and survival rates. According to Roots Analysis, the ...